IPO Quarterly Report
In Q2 2023, emerging markets are thriving amid a slow global IPO market.
In brief
• In the first half of 2023, global IPO volumes fell 5%, with proceeds down 36% YOY.
• The US had its largest offering since November 2021.
• Asia-Pacific continues to dominate with an approximate 60% share of global IPOs.
News
28 June 2023 - Private equity buyouts in the UK healthcare sector including life sciences increased 14%* in Q1 2023 and remain ahead of pre-pandemic levels, even in the face of economic headwinds. With high levels of capital available to be deployed, its expected private equity interest will continue to be elevated, says RSM UK.
July's eNews is here to help you unveil the latest insights for advancing our Life Science Cluster!
• Pioneering partnership will see the delivery of 95,000 square feet of incubator space on the South Bank of London
• Split across two sites, the life sciences facilities will help incubate early-stage companies spun out of King’s College London in a boost for UK life sciences
• Announcement comes just weeks after the government launched a package of measures to turbocharge growth in UK life sciences
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES ADDITIONAL AGREEMENT WITH LEADING BIOPHARMACEUTICAL COMPANY
Cambridge, UK, 5 July 2023. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has entered into an agreement with a leading biopharmaceutical company to support the ongoing development of a biosimilar product.
Members of the Domainex team supported their local community by volunteering at Sawston Village College. They helped to paint fences, build raised flower beds and did plenty of weeding! Check out the team photo on the Domainex Twitter page!
The DIAMOND Study
The Quadram Institute are looking for volunteers, based in the UK, to take part in a study investigating how our genes and diet influence the risk of dementia, and the role of the gut microbiome in this.
This study can be carried out fully remotely from your own home.
Suzanne Holden, Vice President, Corporate Accounts & Country Leader United Kingdom at Thermo Fisher Scientific, shares her thoughts on why she is excited about the research and investment in predictive genomics. Read this short article that discusses: addressing unmet needs, improving patient outcomes; polygenic risk scores - stratifying the population and from drug discovery to clinical though validation: 'The future, now: Revolutionising disease prevention through predictive
London, July 3rd - Kadans Science Partner will add Harrow House in Oxford, UK to its Pan-European portfolio. The asset will be acquired from Oxford Biomedica in a sale and lease back transaction. Harrow House is a purpose-built manufacturing facility which will be leased back, in its entirety, to Oxford Biomedica. Oxford Biomedica is a quality and innovation-led viral vector CDMO, providing development and manufacturing expertise to some of the world’s most innovative pharmaceutical and biotechnology companies.
Stevenage Bioscience Catalyst is a renowned hub for life sciences in the UK and is recognised as being on par with other established EU clusters specialising in cell and gene therapy.
Read more about how their exciting developments and opportunities for collaboration is making them a centre for excellence.